Primary CNS lymphoma
C Grommes, LM DeAngelis - Journal of Clinical Oncology, 2017 - ascopubs.org
Primary CNS lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is
typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic …
typically confined to the brain, eyes, and cerebrospinal fluid without evidence of systemic …
Primary central nervous system lymphoma
LR Schaff, C Grommes - Blood, The Journal of the American …, 2022 - ashpublications.org
Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphomatous
malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without …
malignancy that affects the brain, spinal cord, leptomeninges, or vitreoretinal space, without …
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 …
AJM Ferreri, K Cwynarski, E Pulczynski, CP Fox… - Leukemia, 2022 - nature.com
Abstract 219 HIV-negative adults≤ 70 years with primary CNS lymphoma (PCNSL) were
enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to …
enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to …
Post‐transplant lymphoproliferative disorders, Epstein‐Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of …
UD Allen, JK Preiksaitis… - Clinical …, 2019 - Wiley Online Library
These updated guidelines from the American Society of Transplantation Infectious Diseases
Community of Practice review the diagnosis, management, and prevention of post …
Community of Practice review the diagnosis, management, and prevention of post …
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients …
AJM Ferreri, K Cwynarski, E Pulczynski… - The Lancet …, 2017 - thelancet.com
Summary Background The International Extranodal Lymphoma Study Group-32 (IELSG32)
trial is an international randomised phase 2 study that addresses two key clinical questions …
trial is an international randomised phase 2 study that addresses two key clinical questions …
Signaling pathways in brain tumors and therapeutic interventions
S Li, C Wang, J Chen, Y Lan, W Zhang… - … and Targeted Therapy, 2023 - nature.com
Brain tumors, although rare, contribute to distinct mortality and morbidity at all ages.
Although there are few therapeutic options for brain tumors, enhanced biological …
Although there are few therapeutic options for brain tumors, enhanced biological …
Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF …
C Houillier, L Taillandier, S Dureau, T Lamy… - Journal of clinical …, 2019 - ascopubs.org
PURPOSE To determine the efficacy and toxicity of chemoimmunotherapy followed by either
whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell …
whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell …
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
K Hoang-Xuan, M Deckert, AJM Ferreri… - Neuro …, 2023 - academic.oup.com
The management of primary central nervous system (PCNSL) is one of the most
controversial topics in neuro-oncology because of the complexity of the disease and the …
controversial topics in neuro-oncology because of the complexity of the disease and the …
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study
JEC Bromberg, S Issa, K Bakunina… - The Lancet …, 2019 - thelancet.com
Background The prognosis for primary CNS lymphoma has improved with the use of high-
dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a …
dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a …
Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children's Oncology Group
PURPOSE The combination of irinotecan, temozolomide, dintuximab, and granulocyte-
macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients …
macrophage colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients …